Advancing antibody drug conjugates in gastrointestinal cancers

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Gastrointestinal (GI) cancers represent a significant global health burden, causing one-fifth of all cancer cases and one-third of cancer-related deaths.
• Systemic treatment options for GI cancers are limited compared to other cancer types.
• Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic class, with recent approvals in various malignancies.

Purpose of the Study:

• To review the current development status of ADCs in GI cancers.
• To identify potential challenges hindering ADC development in this field.
• To discuss strategies for optimizing ADC therapy in GI oncology.

Main Methods:

• Review of current literature on ADC development in GI cancers.
• Analysis of clinical activity data for ADCs targeting specific biomarkers (Claudin 18.2, CEACAM5, MET).
• Evaluation of the impact of different cytotoxic payloads (tubulin inhibitors vs. topoisomerase I inhibitors) on ADC efficacy.

Main Results:

• ADC development in GI cancers has lagged behind other cancer types, despite their overall promise.
• ADCs targeting Claudin 18.2, CEACAM5, and MET have shown encouraging clinical activity.
• A shift towards topoisomerase I inhibitor payloads in newer ADCs appears to enhance efficacy, particularly in GI adenocarcinomas.

Conclusions:

• ADCs represent a rapidly evolving therapeutic modality with significant potential in GI oncology.
• Overcoming development hurdles and optimizing payload selection are crucial for realizing the full potential of ADCs in treating GI cancers.
• Emerging solutions and strategies are needed to advance ADC therapy for patients with GI malignancies.